Piper Sandler Raises Target Price for Travere Therapeutics to $48 Amid Positive Pipeline Developments

Piper Sandler has raised its price target for Travere Therapeutics (TVTX) to $48, up from a previous target of $40, citing strengthened conviction in the company’s development pipeline and strategic positioning in rare disease therapeutics. The firm's equity research team highlighted recent progress in the Phase 3 development of TVTX’s lead asset, with top-line data expected by mid-2026, as a key driver behind the upgrade. This marks a 20% increase in the target price, signaling growing analyst optimism despite the stock’s recent consolidation near $35. The firm maintains an 'Overweight' rating on the stock, emphasizing the potential for significant upside if upcoming clinical milestones are met. The upgrade comes amid a broader reevaluation of biotech valuations, particularly for companies with niche therapeutic focus and near-term data-readouts. TVTX’s portfolio includes treatments for rare inflammatory and neurological disorders, with a strong commercial presence in the U.S. and emerging markets. Piper Sandler noted that the company’s ability to maintain revenue growth through effective patient access programs and expanded indications could support sustained margin expansion. The firm estimates that TVTX’s revenue could reach $280 million by 2027, underpinned by double-digit growth in its core product line. The stock has seen modest trading volume gains since the announcement, with options activity reflecting increased interest in call options expiring in Q3 2026. Institutional investors have maintained a steady ownership stake, with no major changes in holdings reported in the latest Form 13F filings. Market participants are closely monitoring the company’s upcoming regulatory submissions and potential partnerships, which could further accelerate revenue growth. The upgrade underscores a shift in sentiment toward high-conviction biotech names with de-risked pipelines and clear path to commercialization.